FDA Approves Zepbound for Sleep Apnea in Patients With Obesity
By Physician’s Briefing Staff HealthDay Reporter
MONDAY, Dec. 23, 2024 -- The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
In a news release published Dec. 20, the FDA stated that Zepbound, a glucagon-like peptide-1 receptor agonist, was cleared to treat moderate-to-severe OSA in patients with obesity. According to drugmaker Eli Lilly, the treatment is intended for use alongside a reduced-calorie diet and increased physical activity.
"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical Care in the FDA Center for Drug Evaluation and Research, said in a news release. "This is a major step forward for patients with obstructive sleep apnea."
"Many cases of OSA go undiagnosed and untreated, leaving millions at risk for serious health consequences," Patrik Jonsson, president of Lilly Cardiometabolic Health, said in a news release from the company. In clinical trials, he noted, nearly half of Zepbound users saw such significant improvements that their OSA symptoms resolved.
FDA approval for Zepbound in treating sleep apnea was based on two previous Eli Lilly-sponsored trials published in the New England Journal of Medicine involving nearly 470 participants, some of whom were using continuous positive airway pressure (CPAP) machines.
In one trial in which participants did not use CPAP, Zepbound reduced apnea-hypopnea index events by an average of 25 per hour after one year compared with a reduction of just five events in the placebo group. In the trial involving CPAP users, Zepbound reduced events by 29 per hour on average versus six in the placebo group.
The FDA approval is only for people with obesity, but it could help those with sleep apnea get Medicare coverage, which currently does not cover drugs just for weight loss.
Eli Lilly has emphasized its commitment to accessibility, offering patient support programs, including a lower-cost vial option, to help ease financial barriers. However, without insurance, monthly costs can still exceed $1,000.
Approval of this indication for Zepbound was granted to Eli Lilly.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Adenotonsillectomy Tied to Lower Health Care Use in Pediatric Sleep Disordered Breathing
MONDAY, March 17, 2025 -- For children with mild sleep disordered breathing (SDB), adenotonsillectomy is associated with reduced all-cause health care utilization, according to a...
AAN: Obstructive Sleep Apnea Linked to Increased Incidence of Parkinson Disease
TUESDAY, March 4, 2025 -- Obstructive sleep apnea (OSA) is associated with an increased risk for Parkinson disease (PD), according to a study scheduled for presentation at the...
Tonsillectomy Effective for Nocturnal Enuresis in Children With Sleep Apnea
FRIDAY, Feb. 7, 2025 -- For children with obstructive sleep apnea (OSA) with nocturnal enuresis (NE), the remission rate of NE is more than half for those undergoing adenoidectomy...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.